The introduction of HER2-targeted therapies, including monoclonal antibodies such as trastuzumab and pertuzumab, has significantly improved clinical outcomes for HER2-positive breast cancer patients by directly inhibiting HER2-mediated signaling [14,15]. This evidence concerns the gene ERBB2 and breast carcinoma.